These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 159041)

  • 21. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological fibrinolysis.
    Fletcher AP
    Fed Proc; 1966; 25(1):84-8. PubMed ID: 4283650
    [No Abstract]   [Full Text] [Related]  

  • 23. [Fibrinolysis: some new facts and ideas].
    Kopec M
    Postepy Hig Med Dosw; 1975; 29(1):77-90. PubMed ID: 123072
    [No Abstract]   [Full Text] [Related]  

  • 24. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mechanism of thrombolytic enzymes].
    Matsuo O
    Rinsho Ketsueki; 1993 Apr; 34(4):395-402. PubMed ID: 8510325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Enzymatic determination of plasminogen activators].
    Fischer BE
    Z Med Lab Diagn; 1988; 29(6):327-32. PubMed ID: 2973186
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies on platelet aggregation inhibitors in vivo. X. Relationship to thrombolysis.
    Ambrus JL; Ambrus CM; Sharma SD; Suh OW; Gastpar H
    J Med; 1982; 13(5-6):365-71. PubMed ID: 6221055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinolysis in the pigeon (Columba livia).
    Ahmad N; Dube B; Agarwal GP; Dube R
    Thromb Haemost; 1979 Oct; 42(3):955-8. PubMed ID: 505408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New method of studying the release of fibrinolysis activators in tissue cultures].
    Pandolfi M; Astedt B
    Biull Eksp Biol Med; 1977 Aug; 84(8):250-3. PubMed ID: 907833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment.
    Gandorfer A; Kampik A
    Retina; 2005; 25(2):232-3; author reply 233-4. PubMed ID: 15689824
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effects of intravitreal injection of urokinase on the rabbit eye. II. Effects of urokinase with stabilizer on ERP amplitude].
    Tamai A; Ueno H; Noda K; Kishi S; Iyota K; Masaoka N; Wada H
    Nippon Ganka Gakkai Zasshi; 1983; 87(10):974-82. PubMed ID: 6673551
    [No Abstract]   [Full Text] [Related]  

  • 35. Localization and distribution of fibrinolysis inhibition in the walls of human arteries and veins.
    Hegt VN
    Thromb Res; 1977 Jan; 10(1):121-33. PubMed ID: 139705
    [No Abstract]   [Full Text] [Related]  

  • 36. Intravitreal fibrinolysis in experimental vitreous haemorrhage.
    Forrester JV; Edgar W; Prentice CR; Forbes CD; Williamson J
    Exp Eye Res; 1976 Feb; 22(2):181-8. PubMed ID: 1269542
    [No Abstract]   [Full Text] [Related]  

  • 37. Measurement of degraded forms of plasminogen in human plasma.
    Scully MF; Kakkar VV
    Thromb Res; 1980 Feb 1-15; 17(3-4):347-52. PubMed ID: 6768159
    [No Abstract]   [Full Text] [Related]  

  • 38. Retinal cryoapplication and fibrinolysis in experimental vitreous hemorrhage.
    Guerra A; Pastor JC
    Curr Eye Res; 1991 Aug; 10(8):697-701. PubMed ID: 1914503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PROLONGED HYPERPLASMINEMIA WITH MITOMYCIN C IN RABBITS. REVERSIBLE DISAPPEARANCE OF TISSUE ACTIVATOR IN PARENCHYMA OF KIDNEY.
    OKAMOTO U; TAKADA Y
    Keio J Med; 1964 Sep; 13():165-72. PubMed ID: 14217475
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of a fibrinolytic agent on vitreous hemorrhage in rabbits.
    Maberley AL; Chisholm LD
    Can J Ophthalmol; 1970 Jan; 5(1):55-64. PubMed ID: 5447399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.